China approves Descovy, Harvoni, Hemlibra

China approves Descovy, Harvoni, Hemlibra

Source: 
BioCentury
snippet: 

China's National Medical Products Administration (NMPA) has issued new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), and Hemlibra emicizumab-kxwh from Roche (SIX:ROG; OTCQX:RHHBY).